Search

Search Constraints

You searched for: Author/Creator Evans, Tamasin

Search Results

1. Adjuvant durvalumab post-chemoradiotherapy in stage III non-small cell lung cancer: experience from the Edinburgh Cancer Centre. (March 2022)

3. Biomarkers of systemic inflammation predict survival in stage III non-small cell lung cancer treated with chemoradiotherapy. (March 2022)

5. Gross tumour volume predicts survival and correlates with pre-treatment serum albumin concentration in patients with stage III non-small cell lung cancer treated with chemo-radiotherapy. (March 2022)

6. Pre-treatment serum albumin is a prognostic biomarker for locally advanced non-small cell lung cancer: extended follow up of patients treated with concurrent chemo-radiotherapy. (June 2021)

7. Quality of life after breast-conserving therapy and adjuvant radiotherapy for non-low-risk ductal carcinoma in situ (BIG 3-07/TROG 07.01): 2-year results of a randomised, controlled, phase 3 trial. Issue 5 (May 2020)

8. Real world prospective data on tyrosine kinase inhibitors in the treatment of epidermal growth factor receptor mutation positive non-small cell lung cancer at the Edinburgh Cancer Centre. (June 2021)

9. Real-world outcomes for patients with inoperable stage III non-small cell lung cancer: a prognostic role for albumin?. (March 2022)

10. Scottish Immunotherapy Prognostic Score: biomarker of systemic inflammation predicts response to first-line pembrolizumab for metastatic non-small cell lung cancer. (June 2021)